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The staging of hepatic fibrosis is a cornerstone of prognosis and assessment of disease 
progression in those with chronic liver diseases including nonalcoholic steatohepatitis 
(NASH). This is so because a histological assessment of fibrosis has been the only clinically 
applicable readout of such progression over the last century. The last ten years have, 
however, seen numerous changes that have challenged classical paradigms and are creating 
new norms for the evaluation of progression and regression of chronic liver diseases.
Much of the impetus for the development of newer ways to assess disease progression comes 
from the inadequacies of liver biopsies as the gold standard for evaluating hepatic fibrosis.1 
Liver biopsies often yield a core of 1–2 mm diameter and a length varying 1 to 2 cm.2 While 
there has been tacit acceptance that this reflects what is happening in the entire liver, it is 
now well established that there is substantial sampling variability associated with biopsies in 
routine settings.2 Specifically, in those with NASH, it has been shown that two biopsies 
performed at the same location can be associated with a one-stage variability in fibrosis in 
36%, and a two-stage variation is assessment of fibrosis in 35%.3 Also, the biopsy length is 
a critical determinant of the risk of under- or over-assessment of hepatic fibrosis with cores 
less than 1 cm length often providing uninterpretable information.2, 3 On the other hand, 
when the core approaches 4 cm length and an asymptote in error rates is reached, there 
remains substantial baseline variability in fibrosis assessment.4 Liver biopsies are also 
uncomfortable and occasionally accompanied by severe morbidity and rare mortality. These 
have hindered widespread use of this technique for evaluation of abnormal liver enzymes in 
the general population. With the growing epidemic of NASH which is estimated to affect 3–
5% of the general population,5 there is also a lack of trained workforce that can perform and 
evaluate biopsies even when they are done.
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From a clinician’s perspective, the key question is whether a given patient is progressing 
towards cirrhosis and how close they are to having a liver related adverse event. Answering 
the question drives management of the patient to prevent complications of advanced liver 
disease. Vibration-controlled transient elastography (VCTE) by Fibroscan is one such 
promising technology that has been available for use over the last decade.6 It was, however, 
only recently approved by the regulatory authorities for use through a 510(k) clearance by 
the U.S. Food and Drug Administration (FDA). In order to overcome the learning curve 
effect, the FDA-manufacturer agreement requires that an operator undergo course training 
and perform a minimum of 10 cases under supervision of a proctor before being able to use 
the device independently. The Fibroscan device works on the simple concept of transmitting 
a vibration of mild amplitude at low frequency to induce an elastic shear wave and measure 
the speed of propagation using a pulse-echo ultrasonic acquisition.6 In simple terms, the 
velocity of the wave propagation directly relates to the tissue stiffness. The device also 
acquires information from approximately 100 times more sample tissue than a liver biopsy, 
potentially minimizing the risk of sampling error.6 It is also rapid, noninvasive, and can 
easily be performed at bedside. The availability of the results for immediate discussion with 
the patient during the visit is very convenient and offers an opportunity for the patient to be 
involved in the decision process.
Liver stiffness measurement (LSM) by VCTE using Fibroscan serves as a surrogate for 
degree of fibrosis.6 It is generally considered to be reproducible,7 and several cross-sectional 
studies have reported good correlation with underlying liver fibrosis with disease-specific 
cut-offs.8–11 A recent study not only showed good correlation with severity of primary 
sclerosing cholangitis at baseline but also showed that the incremental change in the LSM 
(ΔLSM/∂t) was predictive of disease progression and clinical outcomes.10 Serial 
measurements of LSM may thus become an integral part of management of chronic liver 
disease, both for assessment of severity and monitoring of response. It is in this context that 
the current study by Nascimbeni et al. finds critical relevance.12 In this retrospective analysis 
of an existing database of VCTEs performed using Fibroscan at the investigator’s institution 
over several years, the authors examined the short-term variability (>1 day and <1 year) in 
LSM in 531 pairs of LSMs obtained in 432 untreated, clinically stable, immunocompetent 
patients with various chronic liver diseases. The two measurements i.e., first LSM (LSM1) 
and second LSM (LSM2) were not statistically significantly different to raise concern about 
the variability in the LSM measurement not related to disease progression. Although 
reassuring at the study population level, a variability of >20% was seen in almost half, >30% 
in one-third and >50% in up to 12% in the paired measurements. This variability was 
constant across the spectrum of LSM1 values. This variability resulted in fibrosis 
classification change by one stage in 30% and two or more stages in up to 10%. Predictors 
of variability were: two different operators, at least one non-senior operator, the interquartile 
range/median ratio, first LSM (LSM1) showing ≥7 kPa, baseline BMI, and doubling of LAT 
between paired measurements. The authors conclude that monitoring of fibrosis by VCTE 
using Fibroscan could be altered by clinically significant variability unrelated to the natural 
course of the disease and associated with operator and patient-related factors. The lowest 
variability was seen in patients with no/early fibrosis and when VCTE was performed by a 
single experienced operator.
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There could be several potential causes of the reported intra-individual variability in the 
VCTE results reported in this study.12 There is both intra- and inter-reporter variability in 
the assessment of fibrosis.12 This may be due in part to varying periods of fasting prior to 
the studies, variability in positioning both the subject and the probe. Also, in the context of 
NASH, the impact of changing hepatic fat content on the fibrosis readout by VCTE is not 
well characterized and may have contributed to the observed variability. There are also other 
conditions that can affect the VCTE results including hepatic congestion due to heart 
disease, infiltrative disorders etc.13 An in depth review of these factors was recently 
published.14 Finally, the study was performed only with the medium probe in a variety of 
liver disorders and no disease-specific cut-offs were implemented in staging of the fibrosis.
These factors highlight the need to develop standardized protocols for performance of VCTE 
and the reporting of metrics associated with the quality of the study procedure.14 Normally, 
VCTE should be performed with the patient in a fasting condition for two hours before the 
procedure, lying in supine position with normal breathing, with right arm in maximum 
abduction to allow optimal exposure of right lateral abdomen. It is also important to 
maximize the amount of liver tissue interrogated and to avoid the lower edge of the liver. It 
is possible that for those where multiple studies are anticipated, the location of where the 
probe was placed is noted in the report to help the next operator perform the study optimally. 
Furthermore, the median and interquartile range of results must be reported; every attempt 
should be made to keep the variance in VCTE measurements to a minimum and ideally 
under 10%.14
There is increasing use of VCTE in the everyday management of patients with chronic liver 
disease from varied etiology.9, 15, 16 The variability reported in the current study should be 
of concern to clinicians who are using LSM to make decisions with meaningful impact.12 
The current study highlights the short term variability in LSM measurements but does not 
account for many of the variables related to 4Ts (Table 1). With this study, the assumption 
(myth) of reproducibility of VCTE has been challenged, bringing attention to the gaps in 
knowledge (mystery) that need to be resolved to establish the use of VCTE in clinical 
practice. Until such time, we recommend that a good clinical and medication history 
followed by an imaging study, hepatic panel, and etiology specific serologic work-up, be 
available to pursue a context-related interpretation of LSM (wand) and the selective use of 
liver biopsies to maximize their diagnostic yield in a manner that will guide management.
Abbreviations
AST Aspartate aminotransferase
LSM Liver Stiffness Measurement
NAFLD Non-alcoholic fatty liver disease
NASH Non-alcoholic steatohepatitis
PSC Primary Sclerosing Cholangitis
VCTE Vibration Controlled Transient Elastography
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Table 1
The 4Ts: List of variables that could affect the liver stiffness measurement or its interpretation when using 
vibration-controlled transient elastography.
Technology Technician/Technique Tissue Tablets/Tonics
Shear wave propagation Operator experience Probe to liver distance Medication usage
TM mode Variability17  -Ascites  -Beta Blockers18
A mode  -Intra-operator  -Adiposity Etiology specific therapy
Algorithm  -Inter-operator  -Altered anatomy Significant weight loss
Software Acute hepatitis19  -Bariatric surgery
Probe size20 Cholestasis21 Excessive alcohol use22
 -Medium Portal flow
 -Extra-large
 -Postprandial state23
TIPSS
Tumor
Cysts
Infiltrative liver disease
Hemangioma24
Congestive hepatopathy13
?Hepatic steatosis
TIPSS: Transjugular intrahepatic portosystemic shunt, HCV: Hepatitis C virus
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